Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« One More on That Buckyball Longevity Paper | Main | The UK Goes Open-Access »

May 10, 2012

GSK Goes Hostile

Email This Entry

Posted by Derek

I mentioned the other day that Human Genome Sciences had turned down an offer from GSK, feeling that they could do better. Well, if they can, now's the time: GSK is now offering the same deal ($13/share) on the open market in a hostile takeover attempt. One of these companies is wrong about that price, and now I guess we'll find out which one of them it is. . .

Comments (6) + TrackBacks (0) | Category: Business and Markets


COMMENTS

1. PharmaTwoPointZero on May 10, 2012 7:40 AM writes...

Derek, I think this deal will go through, Sir Andrew would not have shown his hand in this manner if he did not feel confident about succeeding, he's the sort of guy who knows what he want and knows how to get it. This also appears to be the final consummation of an already close relationship and is clearly as much in the interests of HGS as GSK. Sir Andrew has spoken many times of his disavowal of mega-mergers in favor of niche deals such as this one. Time will tell where the final price ends up but rest assured that the deal will materialize and will deliver drugs for patients. Watch this space!

Permalink to Comment

2. Calvin on May 10, 2012 9:25 AM writes...

Yay for Sir Andrew!!!! He's my hero.....

Permalink to Comment

3. Rev. Howard Furst on May 10, 2012 9:35 AM writes...

Do not mock Sir Andrew or his sycophants. He is the Chuck Norris of Pharma. Drugs run to discover him.

Permalink to Comment

4. Calvin on May 10, 2012 10:22 AM writes...

I do actually think Sir Andrew is pretty good. Fawning sycophants not so much

Permalink to Comment

5. Anonymous on May 10, 2012 11:06 AM writes...

Chuck Norris! LOL!

Permalink to Comment

6. doctorpat on May 20, 2012 10:19 PM writes...

One of these companies is wrong about that price,

Actually, both companies agree about the price.

HGS thinks that the price is low, which is why they don't want to sell.
And GSK ALSO thinks that the price is low, which is why they want to buy.

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Gitcher SF5 Groups Right Here
Changing A Broken Science System
One and Done
The Latest Protein-Protein Compounds
Professor Fukuyama's Solvent Peaks
Novartis Gets Out of RNAi
Total Synthesis in Flow
Sweet Reason Lands On Its Face